Zacks Investment Research upgraded shares of STRATA Skin Sciences (NASDAQ:SSKN) from a hold rating to a buy rating in a research report sent to investors on Friday, Zacks.com reports. Zacks Investment Research currently has $2.75 price objective on the medical device company’s stock.

According to Zacks, “Strata Skin Sciences, Inc. is a medical technology company which focused on the dermatology market. Its products include the XTRAC laser(R) and VTRAC(R) excimer lamp systems for treatment of psoriasis, vitiligo and other skin conditions as well as the MelaFind (R) system used for identification and management of melanoma skin cancer. Strata Skin Sciences, Inc., formerly known as MELA Sciences, Inc., is based in Horsham, Pennsylvania. “

Other equities research analysts also recently issued reports about the stock. ValuEngine downgraded shares of STRATA Skin Sciences from a buy rating to a hold rating in a research note on Monday, April 1st. Northland Securities reiterated a buy rating and issued a $7.00 target price on shares of STRATA Skin Sciences in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $4.92.

NASDAQ:SSKN traded down $0.01 during mid-day trading on Friday, hitting $2.38. The stock had a trading volume of 216,871 shares, compared to its average volume of 24,323. STRATA Skin Sciences has a twelve month low of $1.45 and a twelve month high of $3.88. The company has a current ratio of 4.54, a quick ratio of 4.03 and a debt-to-equity ratio of 0.22.

Hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in STRATA Skin Sciences by 3,605.7% during the third quarter. Vanguard Group Inc. now owns 593,357 shares of the medical device company’s stock worth $2,100,000 after acquiring an additional 577,345 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in STRATA Skin Sciences by 70.3% during the third quarter. Dimensional Fund Advisors LP now owns 66,813 shares of the medical device company’s stock worth $237,000 after acquiring an additional 27,586 shares during the last quarter. Nantahala Capital Management LLC lifted its position in STRATA Skin Sciences by 8.2% during the fourth quarter. Nantahala Capital Management LLC now owns 2,768,001 shares of the medical device company’s stock worth $7,197,000 after acquiring an additional 209,110 shares during the last quarter. Vanguard Group Inc lifted its position in STRATA Skin Sciences by 3,605.7% during the third quarter. Vanguard Group Inc now owns 593,357 shares of the medical device company’s stock worth $2,100,000 after acquiring an additional 577,345 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in STRATA Skin Sciences during the first quarter worth approximately $39,000. Hedge funds and other institutional investors own 28.23% of the company’s stock.

About STRATA Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, focuses on the therapeutic and aesthetic dermatology market. The company operates through three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment, and Dermatology Imaging. Its products include XTRAC laser and VTRAC excimer lamp systems used for the treatment of psoriasis, vitiligo, and other skin conditions; the STRATAPEN MicroSystems, a micropigmentation device; and Nordlys, a multi-technology aesthetic laser device for treating vascular and pigmented lesions.

Read More: Retained Earnings

Get a free copy of the Zacks research report on STRATA Skin Sciences (SSKN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.